Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 2/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.34 |
| ▸ | TUBB | P07437 | 1/20 | 0.34 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.34 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.34 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.34 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.34 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3374487 | 1.00 | PDGFRB (0.44) | PDGFRBPDGFRANFE2L2GRM4NPC1 | |
| SCHEMBL3606970 | 0.81 | SLC2A1 (0.38) | NPC1RAB9AKCNH2 | |
| SCHEMBL3606967 | 0.81 | SLC2A1 (0.38) | NPC1RAB9AKCNH2 | |
| SCHEMBL592158 | 0.80 | ERN1 (0.41) | KCNH2 | |
| SCHEMBL592871 | 0.80 | KCNH2 (0.38) | KCNH2 | |
| SCHEMBL3255263 | 0.76 | TRPA1 (0.44) | PDGFRBPDGFRANFE2L2GRM4TRPA1 | |
| SCHEMBL3255262 | 0.76 | TRPA1 (0.44) | PDGFRBPDGFRANFE2L2GRM4TRPA1 | |
| SCHEMBL591038 | 0.74 | FDPS (0.41) | CYP1A2KCNH2 | |
| SCHEMBL591037 | 0.74 | FDPS (0.41) | CYP1A2KCNH2 | |
| SCHEMBL14126236 | 0.73 | KCNH2 (0.39) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012040321-A3 | METHODS AND APPARATUS FOR EHNANCED GAS DISTRIBUTION | GRUPO PETROTEMEX, S.A. DE C.V. (MX) | 2012-05-10 | — | — | WO | disclosed |
| EP-1981881-B1 | TETRAHYDROPYRANE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-12-07 | — | — | EP | disclosed |
| EP-1987040-B1 | ETHANOL OR 1,2-ETHANEDIOL CYCLOHEXYL ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-10 | — | — | EP | disclosed |
| US-7820655-B2 | Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20090005368-A1 | such as 6-({trans-4-[(1R)-1-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-cyclohexylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one for treating infections from Streptococcus pneumoniae, Haemophilus influenzae, Moraxella, Staphylococcus, Enterococcus | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-01-01 | — | — | US | disclosed |
| EP-1996579-A2 | ANTIBIOTIC COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2008-12-03 | — | — | EP | disclosed |
| EP-1987040-A1 | ETHANOL OR 1,2-ETHANEDIOL CYCLOHEXYL ANTIBIOTIC DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2008-11-05 | — | — | EP | disclosed |
| EP-1981881-A1 | TETRAHYDROPYRANE ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007105154-A2 | ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007093963-A1 | ETHANOL OR 1,2-ETHANEDIOL CYCLOHEXYL ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-23 | — | — | WO | disclosed |
| WO-2007086016-A1 | TETRAHYDROPYRANE ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-02 | — | — | WO | disclosed |
| EP-1799676-A2 | NEW BICYCLIC ANTIBIOTICS | Actelion Pharmaceuticals Ltd. (CH) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006032466-A2 | NEW BICYCLIC ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005368-A1 | such as 6-({trans-4-[(1R)-1-hydroxy-2-(3-methoxy-quinolin-5-yl)-ethyl]-cyclohexylamino}-methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one for treating infections from Streptococcus pneumoniae, Haemophilus influenzae, Moraxella, Staphylococcus, Enterococcus | RBPJ, RXRA, MRPL21 | PDGFRB 3877/4885PDGFRA 3584/4885NFE2L2 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.